Together, we can START on a new path to treating Alzheimer’s disease.
Take part in a research study testing an investigational treatment that may slow the process of memory loss caused by Alzheimer’s disease.
START STUDY
The START (Synaptic Therapy Alzheimer’s Research Trial) Study is testing an investigational treatment to see if it can help slow memory loss caused by Alzheimer’s disease (AD). Scientists believe the investigational treatment, also called the study drug, works in a different way than other drugs used to treat AD. The drug does not have a name yet, so for now it is called CT1812. It comes in the form of a capsule, and it is not approved for use outside of a research study.
GOAL OF THE STUDY
The purpose of the START Study is to test CT1812 to see if it may potentially be used to treat people with early AD.
Reasons to Join
Help find out if CT1812 is an effective treatment
Because the average age of people in the U.S. is rising, the number of people with AD is expected to increase a lot in the coming years. Participation in the START Study will help determine if treatment with CT1812 can help slow the process of memory loss caused by AD.
Contribute to important new research
By participating in the START Study, you or your loved one may not directly benefit but could be an important part of finding new treatments for people with AD.
Help your community and future generations
The START Study research team is committed to fairness, inclusion, and diversity. We seek people from every race, ethnicity, gender, sexual orientation, economic background, and geography to discover a treatment that is safe and effective for everyone. Each person who joins the study, or helps a loved one take part, helps make sure their community is included in this research and may benefit from it.
Click below for more information about joining the START Study.